Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ribosomal proteins (RP) S13 and
RPL23
were previously identified as two upregulated genes in a multidrug-resistant gastric cancer cell line SGC7901/VCR compared to its parental cell SGC7901 by differential display PCR. The aim of this study was to explore the roles of RPS13 and
RPL23
in multidrug resistance (MDR) in gastric cancer cells. RPS13 and
RPL23
were genetically overexpressed in SGC7901 cells, respectively. Either RPS13 or
RPL23
enhanced resistance of SGC7901 cells to vincristine, adriamycin, and 5-fludrouracil.
RPL23
also enhanced resistance of SGC7901 cells to cisplatin. Overexpression of either RPS13 or
RPL23
did not alter the population doubling time, [3H]leucine incorporation, and intracellular adriamycin accumulation of SGC7901 cells. However, either RPS13 or
RPL23
could protect SGC7901 cells from undergoing vincristine-induced apoptosis. Western blot analysis revealed that both RPS13 and
RPL23
significantly increased the expression level of
Bcl-2
and
Bcl-2
/Bax ratio in SGC7901 cells. In addition, overexpression of
RPL23
enhanced glutathione S-transferase (GST) activity and intracellular glutathione content in SGC7901 cells. Together, this work demonstrates that either RPS13 or
RPL23
can promote MDR in gastric cancer cells by suppressing drug-induced apoptosis, and that
RPL23
may also promote MDR in gastric cancer cells through regulation of glutathione S-transferase-mediated drug-detoxifying system.
...
PMID:Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. 1514 63